Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019
R

Combination Therapeutic Strategies in Recurrent Ovarian Cancer: (Platinum-Based) Chemotherapy, IO and PARPi

By Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019 FEATURING Robert Coleman
By Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019 FEATURING Robert Coleman
1,546 views
May 29, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

23:46
AstraZeneca Oncology

First-line Maintenance Treatment Option in Patients With HRD-Positiv…

Feat. S. Lewin

Featured Video

19:51
AstraZeneca Oncology

Management Strategies for Fatigue and Asthenia in First-line Mainten…

Feat. D. Czel, C. Arn

Related Content

AUTOPLAY
27:04
Fengting Yan

Cancer Screening Molecular Tools

06:07
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Key Updates in Gynecological Cancers"

Feat. M. Raza Mirza
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
06:47
UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang
11:15
Total Health

2024 Updates in Ovarian Cancer

Feat. T. Tillmanns
06:50
Fengting Yan

Year in Review: Ovarian Cancer

25:10
Yale School of Medicine

Ovarian Cancer Prevention and Early Detection - Ovarian Cancer Does …

Feat. M. Minkin, E. Ratner
15:14
Brian Slomovitz

Update in Vulvar and Vaginal Cancer

06:23
Total Health

Recent Highlights in Ovarian Cancer

Feat. B. Slomovitz
28:11
OncoAlert

Ovarian Cancer: Setting a New Standard of Care

Feat. M. Raza Mirza
18:16
Insights from 2024 ESGO Annual Meeting

ESGO 2024 Insights: "Antibody-Drug Conjugates in Ovarian Cancer…

Feat. J. Kurtz
05:09
Insights from 2024 SGO Annual Meeting

SGO 2024 Insights: "Final OS Data of Relacorilant, a Selective …

Feat. N. Colombo
15:45
Michael Birrer

Defining Platinum Resistance in Ovarian Cancer

05:32
Insights from 2023 ESMO Asia Annual Meeting

LARA Trial: Preliminary Efficacy of Pembro + Lenvatinib in Recurrent…

Feat. N. Ngoi
23:35
Kathleen Moore

How to Select the Best Maintenance Treatment in Patients With Ovaria…

09:42
Erin Crane

Niraparib as 1L Maintenance Treatment for Advanced Ovarian Cancer

17:06
Ovarian Cancer Midwest Focus, University of Minnesota

Novel ADCs in Ovarian Cancer: A New Treatment Modality

Feat. S. Lheureux
10:27
Robert McBane

2023 ISTH Insights: "The EVE Trial - Extending VTE Secondary Pr…

08:37
Fred Hutchinson Cancer Center

Niraparib as 1L Maintenance Treatment for Advanced Ovarian Cancer: D…

Feat. K. Banda
12:21
Insights from 2024 ESGO Annual Meeting

ESGO 2024 Insights: "PARP Inhibitor Resistance Mechanisms in Gy…

Feat. V. Heinzelmann-Schwarz